AU2001262984A1 - Treatment of hypertriglyceridemia and other conditions using lxr modulators - Google Patents

Treatment of hypertriglyceridemia and other conditions using lxr modulators

Info

Publication number
AU2001262984A1
AU2001262984A1 AU2001262984A AU6298401A AU2001262984A1 AU 2001262984 A1 AU2001262984 A1 AU 2001262984A1 AU 2001262984 A AU2001262984 A AU 2001262984A AU 6298401 A AU6298401 A AU 6298401A AU 2001262984 A1 AU2001262984 A1 AU 2001262984A1
Authority
AU
Australia
Prior art keywords
hypertriglyceridemia
treatment
conditions
lxr modulators
lxr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001262984A
Other languages
English (en)
Inventor
Joshua Schultz
Bei Shan
Hua Tu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc filed Critical Tularik Inc
Publication of AU2001262984A1 publication Critical patent/AU2001262984A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001262984A 2000-05-03 2001-05-03 Treatment of hypertriglyceridemia and other conditions using lxr modulators Abandoned AU2001262984A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20160100P 2000-05-03 2000-05-03
US60201601 2000-05-03
PCT/US2001/014586 WO2001082917A2 (fr) 2000-05-03 2001-05-03 Traitement de l'hypertriglyceridemie et d'autres maladies au moyen de modulateurs lxr

Publications (1)

Publication Number Publication Date
AU2001262984A1 true AU2001262984A1 (en) 2001-11-12

Family

ID=22746500

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001262984A Abandoned AU2001262984A1 (en) 2000-05-03 2001-05-03 Treatment of hypertriglyceridemia and other conditions using lxr modulators

Country Status (3)

Country Link
US (1) US20020048572A1 (fr)
AU (1) AU2001262984A1 (fr)
WO (1) WO2001082917A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101933D0 (en) * 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
WO2003059874A2 (fr) 2001-12-21 2003-07-24 Pharmacia Corporation Modulateurs du recepteur x du foie de thioether aromatique
CA2469435A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
ATE521599T1 (de) 2001-12-21 2011-09-15 X Ceptor Therapeutics Inc Heterocyclische modulatoren von nukleären rezeptoren
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2486651A1 (fr) * 2002-05-24 2003-12-04 Pharmacia Corporation Modulateurs de recepteur x hepatique a base de sulfone
MXPA04011691A (es) * 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
EP1542966A1 (fr) * 2002-09-17 2005-06-22 Pharmacia Corporation Modulateurs des recepteurs hepatiques x aromatiques
EP1572660B1 (fr) 2002-12-20 2011-01-26 X-Ceptor Therapeutics, Inc. Dérives d'isoquinolinone et leur utilisation comme agents thérapeutiques
AU2003301216A1 (en) * 2002-12-23 2004-07-22 Irm Llc Novel use of liver x receptor agonists
WO2004072046A2 (fr) * 2003-02-12 2004-08-26 Carex S.A. Modulation de l'activite des recepteurs nucleaires
WO2004072042A2 (fr) * 2003-02-12 2004-08-26 Carex S.A. Modulation de l'activite de recepteurs nucleaires
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
EP1758651A2 (fr) * 2004-06-24 2007-03-07 Galapagos N.V. Procedes et compositions permettant de favoriser l'homeostasie osseuse
CA2613522A1 (fr) 2005-06-27 2007-01-04 Exelixis, Inc. Regulateurs de lxr de type imidazole
ES2438739T3 (es) * 2005-06-28 2014-01-20 Daiichi Sankyo Company, Limited Procedimiento de prueba de ligando LXR
CA2615718A1 (fr) * 2005-07-22 2007-02-01 Amgen Inc. Derives de sulfamide d'aniline et leurs utilisations
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0716833A2 (pt) * 2006-09-19 2013-11-05 Wyeth Corp Uso de agonistas de lxr para o tratamento de osteoartrite
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
ES2620451T3 (es) 2009-05-28 2017-06-28 Exelixis Patent Company Llc Moduladores de los LXR
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CN104619350A (zh) 2012-06-14 2015-05-13 Ambrx公司 结合到核受体配体多肽的抗psma抗体
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
US9834542B2 (en) 2013-03-15 2017-12-05 Bristo-Myers Squibb Company LXR modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU6074700A (en) * 1999-07-08 2001-01-30 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
EP1239848A2 (fr) * 1999-09-01 2002-09-18 University of British Columbia Compositions et methodes permettant de moduler le taux de hdl cholesterol et de triglycerides

Also Published As

Publication number Publication date
WO2001082917A3 (fr) 2002-06-06
US20020048572A1 (en) 2002-04-25
WO2001082917A2 (fr) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001262984A1 (en) Treatment of hypertriglyceridemia and other conditions using lxr modulators
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2001288251A1 (en) Methods and devices for optical stimulation of neural tissues
AU2001283462A1 (en) Treatment of helicobacter with isothiocyanates
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AUPQ544900A0 (en) Treatment of cellulosic material
EP1465869A4 (fr) Modulateurs de lxr
AU2001288387A1 (en) Electronic and optical devices and methods of forming these devices
AU8657601A (en) Composition and method for treatment of hypertriglyceridemia
AU2001288299A1 (en) Electrochromic materials, devices and process of making
AU2001286677A1 (en) Controlled release of substances
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002231206A1 (en) Treatment of depression
AU2001287534A1 (en) Use of flupirtine to treat tinnitus
AU2001234444A1 (en) Car modulators: screening and treatment of hypercholesterolemia
AU2001257138A1 (en) Neutralization of reactive elements
AU2001241771A1 (en) Use of avocado-soybean unsaponifiable preparations
AU2001245414A1 (en) Treatment of allergies
AU2001252627A1 (en) Polybenzasol fiber and use of the same
AU5901100A (en) Micro-electromechanical devices and methods of manufacture
AU2001241630A1 (en) Treatment of inflammation with p20
AUPQ582400A0 (en) A method of treatment and agents for use therein
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
EP1263935A4 (fr) Scytonemine et ses procedes d'utilisation